28th week of 2011 patent applcation highlights part 38 |
Patent application number | Title | Published |
20110171235 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2011-07-14 |
20110171236 | ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USE - Isolated peptides of the | 2011-07-14 |
20110171237 | PHEP, AN AMINO ACID PERMEASE OF STAPHYLOCOCCUS AUREUS - The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. | 2011-07-14 |
20110171238 | NOVEL STRA6 POLYPEPTIDES - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 2011-07-14 |
20110171239 | pH INDUCED SILK GELS AND USES THEREOF - This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to β-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels. | 2011-07-14 |
20110171240 | USE OF CCR9, CCL25/TECK, AND INTEGRIN ALPHA4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified. | 2011-07-14 |
20110171241 | Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies - The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. | 2011-07-14 |
20110171242 | LIGAND FOR HERPES SIMPLEX VIRUS ENTRY MEDIATOR AND METHODS OF USE - A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided. | 2011-07-14 |
20110171243 | COMPOUNDS FOR TREATING AMYLOIDOSES - The present invention relates to the use of mimotopes in the treatment of β-Amyloidoses including but not limited to Alzheimer's disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated Aβ1-40/42, and N-terminally truncated forms AβpE3-40/42, Aβ3-40/42, Aβ11-40/42, AβpE11-40/42 and Aβ14-40/42 without interfering with physiological functions of APP signalling. | 2011-07-14 |
20110171244 | RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMAVIRUS EPITOPES INSERTED IN AN ADENYLATE CYCLASE PROTEIN OR FRAGMENT THEREOF THERAPEUTIC USES THEREOF - The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects. | 2011-07-14 |
20110171245 | RECOMBINANT ANTIGEN FOR DIAGNOSIS AND PREVENTION OF MURINE TYPHUS - The invention relates to a recombinant immunogenic composition from | 2011-07-14 |
20110171246 | Nutritional Supplement to improve supplementary target protein fraction (TPF) delivery, intracellular absorption and utilization - A nutritional supplement includes the primary ingredients: N-acetyl D-glucosamine, cracked cell wall Green Chlorella, Licorice Root Extract, and Potassium Citrate, as well as secondary ingredients: Zinc L-Carnosine, Gamma-Oryzanol and Capsaicin, that improves the bodies uptake, utilization and over-all bioavailability of exogenous target protein fractions (TPF) including but not limited to: glycoproteins,(such as glucosamine) protein isolates as amino acids, glycosaminoglycans (GAG) (including proteoglycans, and mucopolysaccharides), and polysaccharides such as hyaluronic acid (hyaluronan). The biochemical interactions of the composition improves zeta potential for TPF incorporation in the body through direct and indirect interaction with primary cellular and digestive sites of multiple species. This facilitates greater passage of target protein substrates fractions and isolates into the bloodstream, provides superior intracellular absorption and utilization thereby potentiating the therapeutic effects of TPF systemically. | 2011-07-14 |
20110171247 | Novel vascular endothelial growth factor expression inhibitors - The invention provides anti-aging agents, angiogenesis inhibitors and vascular endothelial growth factor (VEGF) expression inhibitors containing one or more galenicals selected from the group consisting of | 2011-07-14 |
20110171248 | SYNTHETIC VIRUS-LIKE PARTICLES CONJUGATED TO HUMAN PAPILLOMAVIRUS CAPSID PEPTIDES FOR USE AS VACCINES - Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of the synthetic nanocarrier. | 2011-07-14 |
20110171249 | Chimeric chikungunya virus and uses thereof - The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays. | 2011-07-14 |
20110171250 | Synthetic Gene Construct Coding for an HIV1 GAG and Use Thereof for Obtaining Anti-HIV-1 Vaccines - The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines. | 2011-07-14 |
20110171251 | Piscirickettsia salmonis antigens and use thereof - The present invention discloses novel proteins, e.g., antigens, from | 2011-07-14 |
20110171252 | Streptococcus suis vaccines and diagnostic tests - Described are | 2011-07-14 |
20110171253 | NOVEL ASTROVIRUS - This invention relates to the isolation and uses of novel avian astroviruses. The present invention also relates to vaccines, kits and methods for detection of a novel astrovirus. The present invention further relates to vaccination of avians, prevention and/or treatment of avian infections associated with astrovirus. Infections of poultry by this novel astrovirus are associated with runt stunting syndromes. | 2011-07-14 |
20110171254 | CYTOKINE-COATED CELLS AND METHODS OF MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN - The invention relates to a method of vaccinating a mammal to a selected antigen, comprising administering to a mammal a vaccine composition comprising a cytokine-coated cell, wherein the cytokine-coated cell comprises the selected antigen. | 2011-07-14 |
20110171255 | EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS IMMUNOLOGICAL ADJUVANT - The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today. | 2011-07-14 |
20110171256 | VIRAL STRAINS DERIVED FROM THE VACCINIA VIRUS LISTER VACV-107 AND USES THEREOF - The present invention relates to viral strains derived from the vaccinia virus Lister VACV-107 and to pharmaceutical composition containing the viral strains. More particularly, the present invention relates to a viral strain derived from the vaccinia virus Lister VACV-107 wherein strain contains in its genomic sequence (SEQ ID N°1) at least one deletion selected from the group consisting of: deletion of the nucleotides 19758 to 28309 in the sequence ID NO°1 (Δ18), deletion of the nucleotides 161293 to 164811 in the sequence ID NO°1 (Δ20), deletion of the nucleotides 181231 to 183304 in the sequence ID NO°1 (Δ21), deletion of the nucleotides 6118 to 9677 in the sequence ID NO°1 (Δ22), deletion of the nucleotides 1833 to 3574 and 185848 to 187589 in the sequence ID NO°1 (Δ23). | 2011-07-14 |
20110171257 | HERPES SIMPLEX VIRUS AMPLICON VECTORS DERIVED FROM PRIMARY ISOLATES - Provided herein are HSV amplicon particles and methods of making and using HSV amplicon particles. The particles are generated using primary HSV isolates or packaging vectors derived from primary HSV isolates. | 2011-07-14 |
20110171258 | POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND VACCINATION METHODS - Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against HIV is disclosed. The compositions and methods described herein are for the use of a DNA composition that encodes one or more different HIV envelope glycoproteins. The DNA composition can encode an HIV Gag protein. The DNAs encoding one or more HIV proteins are a combination of different nucleic acids, such as DNA plasmids, generated from primary isolate DNA of different HIV major group genetic clades and/or different proteins. HIV protein compositions for inducing an immune response against HIV are disclosed. Methods for using the protein compositions as boosts following administration of the DNA compositions are provided. | 2011-07-14 |
20110171259 | Novel Compositions and Adjuvants - The present invention is directed toward adjuvants that effect an innate and/or a specific immune response. The adjuvants contain at least one lipoprotein, such as Lip, Lip fragments or Lip variants, where the lipoprotein comprises at least one pentameric unit and at least one lipid moiety. Adjuvants wherein the lipoprotein make up at least 10% of the adjuvant by weight/volume are provided. | 2011-07-14 |
20110171260 | INFLUENZA DNA VACCINATION AND METHODS OF USE THEREOF - The present invention relates to an influenza immunogen that includes one or more DNA constructs encoding at least two divergent influenza HAs, wherein each of such one or more DNA constructs encodes one or more of the at least two divergent influenza HAs. Such an immunogen, when administered to a subject, induces an immune response to a plurality of strains of influenza virus, wherein at least one strain of the plurality of strains does not encode any of the divergent influenza HAs encoded by the immunogen. The divergent influenza HAs can be swine influenza HAs or equine influenza HAs, such as influenza H1 HAs or influenza H3 HAs. The invention also relates to a method to use such an immunogen to induce such an immune response as well as to DNA constructs comprising such divergent influenza HAs. Such an immunogen can provide a heterologous as well as a homologous immune response. Such an immunogen can be used to induce an immune response against evolving influenza virus. | 2011-07-14 |
20110171261 | IMMUNOGENIC COMPOSITION - This invention relates to the use of a CCR4 antagonist as an adjuvant, in particular in an immunogenic composition comprising an antigen which elicits an immune response against a pathogen or tumour. | 2011-07-14 |
20110171262 | PARVOVIRAL CAPSID WITH INCORPORATED GLY-ALA REPEAT REGION - Parvoviral capsid with incorporated Gly-Ala repeat region The present invention provides a nucleic acid construct comprising a nucleic acid sequence encoding a parvoviral VP1, VP2 and VP3 capsid proteins comprising an immuno evasion repeat sequence. In addition, the present invention provides a cell comprising such construct, a parvoviral virion comprising a capsid protein that comprises an immune evasion repeat sequence, use of that parvoviral virion in gene therapy and a pharmaceutical composition comprising such parvoviral virion. | 2011-07-14 |
20110171263 | COMPOSITIONS AND METHODS OF USE OF ORF-1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS - The present invention relates to polynucleotides encoding | 2011-07-14 |
20110171264 | Protein Formulation - An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong ligands. | 2011-07-14 |
20110171265 | Composition Comprising Parasite Eggs and Methods for Isolation and Storage of Parasite Eggs - The invention relates to a composition for storage and development of eggs from helminthes parasites, where the composition further comprises a liquid carrier having a pH value of below 7 at a temperature from 10 C to ambient temperature. The liquid carrier can be sulphuric acid, H | 2011-07-14 |
20110171266 | MALARIA VACCINE - The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of develop-ment in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention. | 2011-07-14 |
20110171267 | ANTI-FUNGAL COMPOSITION - A multivalent fungal vaccine comprising one or more heat-inactivated fungal antigens, wherein at least one fungal antigen is effective in producing an immune response in a host when said vaccine is administered orally at a dose that is sufficient for preventing or treating the fungal disease in said host. Also described are methods for making and using an orally available anti-fungal vaccine. | 2011-07-14 |
20110171268 | URICASE COMPOSITIONS AND METHODS OF USE - Compositions containing uricase are disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase are also described. Compositions containing uricase and catalase are also disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase and catalase are also described. | 2011-07-14 |
20110171269 | METHOD FOR MANUFACTURING UNIFORM SIZE POLYMERIC NANOPARTICLES CONTAINING POORLY SOLUBLE DRUGS - The present invention relates to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, and more particularly, to a method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs, including a first step of dissolving a biodegradable polymer in a non-volatile polar organic solvent, a second step of adding poorly soluble drugs to water and the biodegradable polymer solution to produce a dispersion, and a third step of adding the dispersion to emulsifier solutions in a batch under the condition of low mechanical energy level stirring. The polymeric nanoparticles of the present invention is capable of manufacturing nano-sized small and uniform polymeric nanoparticles through a simple method of employing a non-volatile polar solvent, especially a solvent having a polarity similar to that of water, as a solvent for a mixture solution of biodegradable polymer and poorly soluble materials, and using a low mechanical energy condition and batch-adding of dispersion in an emulsifying process. The polymeric nanoparticles of the present invention are advantageous in that the dissolution rate of the poorly soluble drugs contained in polymeric particles is dramatically improved, and the poorly soluble drugs are gradually and steadily released and maintained at a constant density over a long period of time. | 2011-07-14 |
20110171270 | NOVEL SOLID STATE FORMS OF LAQUINIMOD AND ITS SODIUM SALT - Provided herein is a novel crystalline form of laquinimod, process for the preparation, pharmaceutical compositions, and method of treating thereof. Provided also herein are novel amorphous and polymorphic forms of laquinimod sodium, process for the preparation, pharmaceutical compositions, and method of treating thereof. | 2011-07-14 |
20110171271 | Citrate-Based Dialysate Chemical Formulations - The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream. | 2011-07-14 |
20110171272 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF PROSTATICALLY BENEFICIAL THERAPEUTIC AGENTS - According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic/antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders. | 2011-07-14 |
20110171273 | STABLE ANTI-NAUSEA ORAL SPRAY FORMULATIONS AND METHODS - Stable formulations of selective 5-hydroxytryptamine receptor antagonists for oral spray administration for absorption by the oral mucosa and related methods of preparation and administration are provided. A preferred embodiment includes ondansetron in a concentration of about 5.1 to about 5.2% w/w; propylene glycol in a concentration of about 60.1 to about 60.3% w/w; water in a concentration of about 5.3 to about 5.4% w/w; and ethanol in a concentration of about 27.1 to about 27.3% w/w. Additional preferred embodiments are preservative free and/or non-aqueous or primarily non-aqueous. | 2011-07-14 |
20110171274 | Fesoterodine Substantially Free of Dehydroxy Impurity - Provided herein is an impurity of fesoterodine, fesoterodine dehydroxy impurity, 2-[(1R)-3-[bis(1-methylethy)amino]-1-phenylpropyl]-4-methylphenyl isobutyrate, and a process for preparing and isolating thereof. Provided further herein is a highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of fesoterodine dehydroxy impurity, process for the preparation thereof, and pharmaceutical compositions comprising highly pure fesoterodine or a pharmaceutically acceptable salt thereof substantially free of dehydroxy impurity. Provided also herein is a pharmaceutical composition comprising solid particles of pure fesoterodine fumarate substantially free of dehydroxy impurity, wherein 90 volume-percent of the particles (D90) have a size of less than about 200 microns. | 2011-07-14 |
20110171275 | GASTRORETENTIVE DRUG DELIVERY SYSTEM, PREPARATION METHOD AND USE THEREOF - A gastroretentive drug delivery system is provided. Said system comprises a hollow vesicle and a drug-containing layer which surrounds the hollow vesicle. Said hollow vesicle preferably has a single chamber structure. The size in maximal diameter direction of said hollow vesicle is preferably 0.5-3.5 cm. The gastroretentive drug delivery system preferably contains an isolating layer and/or waterproofing layer between the hollow vesicle and the layer containing drug. | 2011-07-14 |
20110171276 | Non-Viral Compositions and Methods for Transfecting Gut Cells In Vivo - The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided. | 2011-07-14 |
20110171277 | WOUND DRESSING HAVING A POLYURETHANE FOAM LAYER AND A COVER LAYER MADE OF THERMOPLASTIC POLYMER - The present invention relates to a layered composite which includes a foam layer and a cover layer. The cover layer includes a thermoplastic polymer and is at least partly bonded directly to the foam layer. The foam layer includes a polyurethane foam obtained by frothing and drying a composition that includes an aqueous, anionically hydrophilicized polyurethane dispersion. | 2011-07-14 |
20110171278 | ANIMAL OLFACTORY REPELLANT COMPOSITION CONTAINING MUSTARD OIL AND EUCALYPTUS OIL - Olfactory animal repellant compositions containing volatile oil of mustard and essential oil of eucalyptus, and methods for using the same are provided. | 2011-07-14 |
20110171279 | POLYETHYLENIMINE BIOCIDES - A family of polyethylenimine biocides of formula (I): | 2011-07-14 |
20110171280 | Antimicrobial Textiles Comprising Peroxide - This invention pertains to method for imparting a durable antimicrobial activity to substrates, particularly textiles. An acetate-free metal and peroxide antimicrobial treatment formulation is prepared by adjusting the pH of a mixture of a metal salt in aqueous hydrogen peroxide to about 7.5. The substrate is treated with the composition and dried to afford the treated substrate with antimicrobial activity. Zinc salts, ions, or complexes are preferred. | 2011-07-14 |
20110171281 | SOFT CAPSULE COMPOSITION AND METHOD OF USE - A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide. | 2011-07-14 |
20110171282 | Materials Comprising Water-Soluble Polymer Particles and Methods of Making and Using Them - One aspect of the invention relates to new materials for storing, protecting, selectively releasing, and applying active ingredients (e.g. pharmaceuticals and other chemicals). In certain embodiments, the invention provides materials impregnated with water-soluble polymer particles which contain active ingredients which may be selectively released and dispensed in response to contact with water or another liquid. | 2011-07-14 |
20110171283 | COMPOSITION CONTAINING AT LEAST ONE NUTRIVITE, AT LEAST ONE DISINFECTING OR DECONTAMINATING, AND/OR AT LEAST ONE PROTEASE-INHIBITING ACTIVE COMPOUND AND/OR ACTIVE COMPOUND COMPLEX - The present invention relates to a composition containing at least one nutritive, at least one disinfecting or decontaminating and/or at least one protease-inhibiting active compound and/or active compound complex for the external care and/or treatment of wounds of the human or animal body. | 2011-07-14 |
20110171284 | POVIDONE-IODINE AND SUCROSE WOUND HEALING DRESSING - The present invention relates to a composition and wound dressing for delivering a composition comprising povidone-iodine and sucrose mixture. The composition is gelled and, in one embodiment, is impregnated on a gauze or other like material for application to an exuding or non-exuding wound. | 2011-07-14 |
20110171285 | Design of Fibrinogen and Fibrinogen Derived Products with Reduced Bacterial Binding by Using Modified Sequences of Fibrinogen Chains - The present invention describes the design and development of new fibrinogen and fibrinogen derived products with significantly reduced binding to bacteria while retaining normal physiological functions by using modified fibrinogen amino acid sequences. The present invention describes modified sequences of Fg γ-chains and β-chains with reduced binding to | 2011-07-14 |
20110171286 | HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation without the additional constituent. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well. | 2011-07-14 |
20110171287 | Use of Oligonucleotides with Modified Bases as Antiviral Agents - The present invention relates to the use of oligonucleotides having modified nucleobases to inhibit gene expression and/or replication of viruses in a subject. The modified nucleobases may be mercapto-modified bases or hydroxy-modified nucleobases. It is contemplated that the oligonucleotides further comprise a nuclease complex which enhances anti-viral activity of the oligonucleotides. | 2011-07-14 |
20110171288 | TOPICAL COMPOSITIONS AND METHODS FOR WHITENING SKIN - Methods and compositions for whitening or brightening skin comprising at least one whitening active contained in association structures. | 2011-07-14 |
20110171289 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2011-07-14 |
20110171290 | INHIBITION OF ANGIOGENESIS AND TUMOR METASTASIS - The present invention relates to an anti L1-CAM antibody for use in a method for the treatment of a disease in a patient which can be treated by inhibition of angiogenesis, wherein the administration of said anti L1-CAM antibody results in the inhibition of angiogenesis and/or tumor metastasis. | 2011-07-14 |
20110171291 | PATHOLOGICALLY-ACTIVATED THERAPEUTICS - Disclosed are methods and compositions for identifying, producing, and using pathologically-activated targeting compounds. Pathologically-activated compounds are compound that only have an effect, or have a disproportionate effect, on a target molecule when a pathological condition exists. | 2011-07-14 |
20110171292 | PEPTIDE COMPOSITIONS AND METHODS OF USE - The present invention provides isolated peptides with at least two cysteine residues capable of forming one or more disulfide bonds. Pharmaceutical compositions comprising the isolated peptides of the present invention are also provided. The invention also provides methods for inhibiting, preventing or improving the pathological or clinical manifestations of cancer or an inflammatory disease or disorder in a subject, comprising administering a peptide of the invention. | 2011-07-14 |
20110171293 | HARD CAPSULE COMPOSITION AND METHOD OF USE - A method for making clear hard vegetarian gelatin free two piece capsules by creating the first phase of the biphasic system using seaweed extract, gellan gum, metallic element, maltol extract, seaweed extract and water. A filler is created for the first phase of the biphasic network by blending water, galactomannan extract, and cellulose. The filler is then mixed into the system forming a biphasic system, a first pin is then dripped into the blend and then a second pin is then dripped into the blend. Blowing hot air on the dipped pins, which then blows away water on the outer surface of the dipped pins to bond and lock moisture to the cellulose. A large diameter capsule piece is removed from the first pin and a small diameter capsule piece is removed from the second pin, wherein each capsule piece has an outer surface which is mechanically and dimensionally stable. | 2011-07-14 |
20110171294 | Enzyme composition and application thereof in the treatment of pancreatic insufficiency - The present invention relates to a composition of at least one protease and a mode of application for treating patients suffering from pancreatic enzyme insufficiency, pancreatitis or cystic fibrosis. The composition of enzymes comprises at least one protease which has a pH optimum below 5.0 and wherein said protease is further active in the presence of pepsin. In a preferred embodiment, said protease is of microbial origin. | 2011-07-14 |
20110171295 | IMMEDIATE RELEASE COMPOSITIONS OF ACID LABILE DRUGS - The present invention provides a method of creating a macro environment in the stomach for immediate release of acid labile compounds stable at alkaline or near alkaline pH comprising the step of administering a composition comprising acid labile compound stable at alkaline or near alkaline pH together with a water soluble buffer, a water insoluble buffer, a disintegrant and pharmaceutically acceptable excipients. The present invention also provides a pharmaceutical composition of a multi component system in which one component essentially contains an acid labile drug and the other component comprises a fast releasing buffer composition along with pharmaceutically acceptable excipients for oral administration and ingestion by a subject, and process for preparing the same. | 2011-07-14 |
20110171296 | METHOD AND PREPARATION FOR BINDING ACETALDEHYDE IN SALIVA, THE STOMACH AND THE LARGE INTESTINE - The object of the invention is the use of compounds comprising one or more free sulphhydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds. | 2011-07-14 |
20110171297 | SUSTAINED RELEASE FORMULATION FOR VENLAFAXINE HYDROCHLORIDE - The invention provides a sustained release composition that; (1). Is free of initially increased drug delivery that occurs (in sustained release systems containing the water soluble drug venlafaxine HCl, known as burst phenomenon, by using a functional core partially or totally coated by a functional coating layer or film. (2). Delivers the drug substance within 24 hours and is therefore suitable for once daily administration of the said drug substance. (3). Exhibits linearity between the strength dosage form and the (total mass of the dosage form, by proportional increase of the amounts of the drug substance and the excipients in the formulation. (4). Is possible to be divided in smaller doses, without affecting the release of the drug substance. The invention provides a sustained release capsule formulation containing an appropriate number of functional complex mini tablets comprising of: (1). A functional core comprising the active ingredient, especially the water-soluble drug Venlafaxine HCl and appropriate excipients. (2). A functional coating layer or film that reduces the initial surface of the core that is available for the release of the water-soluble drug Venlafaxine HCl phenomenon. | 2011-07-14 |
20110171298 | HARD CAPSULE COMPOSITION AND METHOD OF USE - A method for making a clear hard vegetarian gelatin free two piece capsule by creating a first phase network system using a seaweed extract, a galactomannan extract and a rheology modifier. A filler is created for the first phase network by blending a water, a crystalline alcohol, a polysaccharide, and a sugar alcohol at a temperature less than 80 Fahrenheit. The filler is then mixed into the first phase network system forming a biphasic system. Capsules are then formed by dipping conventional moulding pins into the biphasic solution, blowing hot air on the dipped pins in a chamber with a humidity that is no more than 25 percent, blowing away water on the outer surface of the dipped pins to bond and lock moisture to the polysaccharide and removing the capsule pieces from the pins. The two piece capsule has an outer surface which is mechanically and dimensionally stable. | 2011-07-14 |
20110171299 | DOXYCYCLINE METAL COMPLEX IN A SOLID DOSAGE FORM - The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline or a physiologically acceptable salt thereof; (ii) admixing a metal salt with the aqueous solution; (iii) admixing a base to increase the pH of the aqueous solution, thereby forming a suspension of doxycycline metal; and (iv) drying the suspension, thereby forming a dry granulation of doxycycline metal complex. | 2011-07-14 |
20110171300 | DELTA 9 TETRAHYDROCANNABINOL DERIVATIVES - A compound of formula (I) | 2011-07-14 |
20110171301 | F, G, H, I and K Crystal Forms of Imatinib Mesylate - The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans. | 2011-07-14 |
20110171302 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS - Disclosed herein is a method for treating patient suffering from a disorder related to central nervous system with an oral dosage formulation that contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the formulation provides an average blood level C | 2011-07-14 |
20110171303 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT - Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described. | 2011-07-14 |
20110171304 | INJECTABLE BETA-HAIRPIN PEPTIDE HYDROGEL THAT KILLS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - A peptide comprising the sequence VKVKVRVKV | 2011-07-14 |
20110171305 | DEHYDRATED HYDROGEL INCLUSION COMPLEX OF A BIOACTIVE AGENT WITH FLOWABLE DRUG DELIVERY SYSTEM - The invention provides a controlled release biodegradable polymer formulation adapted for administering bioactive agents such as therapeutic proteins to a patient through implantation of a bolus that forms a depot within the patient's body tissues. The formulation includes a dehydrated inclusion complex of the bioactive agent within a hydrogel, wherein the hydrogel can comprise a polymerized polyalkyleneglycolyl diacrylate, and, optionally, polyalkyleneglycolyl monoacrylates, including methacrylates. Alternatively, the hydrogel can comprise hyaluronic acid, chitosan, agarose, polyvinylacetate, polyvinylpyrrolide, or polyvinylalcohol nanoparticles. The bioactive agent can be a macromolecular material, such as a protein. A method of forming the inventive formulation is also provided, as well as a method for using the formulation in the treatment of a malcondition in a patient in need thereof. | 2011-07-14 |
20110171306 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases. | 2011-07-14 |
20110171307 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES - The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases. | 2011-07-14 |
20110171308 | PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL PREPARATION AND PREPARATION METHOD THEREOF - A pH-sensitive solid pharmaceutical composition for oral formulation and preparation method thereof is provided. The solid pharmaceutical composition contains a pharmaceutical active ingredient, a nano-matrix carrier and a pH-sensitive polymer material. | 2011-07-14 |
20110171309 | Compositions and Methods for Composite Nanoparticle Hydrogels - Provided herein are systems, methods, and compositions for composite nanoparticle hydrogel networks and systems responsive to a first temperature. | 2011-07-14 |
20110171310 | HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 2011-07-14 |
20110171311 | STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES - The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. | 2011-07-14 |
20110171312 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE - Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms. | 2011-07-14 |
20110171313 | COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE - The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients. | 2011-07-14 |
20110171314 | NON-VIRAL COMPOSITIONS AND METHODS FOR TRANSFECTING GUT CELLS IN VIVO - The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided. | 2011-07-14 |
20110171315 | Oral recombinant helicobacter pylori vaccine and preparing method thereof - The invention relates to a recombinant protein used for immunoprophylaxis of human | 2011-07-14 |
20110171316 | EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF - Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions. | 2011-07-14 |
20110171317 | METHOD FOR INHIBITING ACCUMULATION OF VISCERAL FAT - Disclosed is: a visceral fat accumulation inhibitor or a food or drink for inhibiting the accumulation of a visceral fat, which composes a fat globule membrane component as an active ingredient; or a agent or food or drink for promoting the increase in the blood adiponection level and/or inhibiting the decrease in the blood adiponection level, which composes a fat globule membrane component as an active ingredient. A fat globule membrane component can inhibit the accumulation of a visceral fat, and/or can promote the increase in or inhibit the decrease in the blood adiponection level. | 2011-07-14 |
20110171318 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF KIDNEY DISEASE - Compositions for preventing or treating kidney disease comprising one or more food ingredients containing relatively low amounts of protein, sodium, and potassium, typically protein in amounts of from about 5% to about 40%, sodium in amounts of from about 0.01% to about 1%, and potassium in amounts of from about 0.01% to about 1%, and methods comprising administering such compositions to patients susceptible to or suffering from kidney disease for the purpose of preventing or treating kidney disease. | 2011-07-14 |
20110171319 | NUTRITIONAL COMPOSITION MADE USING ISOLATED ORGANIC MATTER - Nutritional compositions, formulations, and intermediates are provided which may be utilized to formulate various sweeteners and other products. The formulations described herein are made from constituents found in soils or fossilized soils. | 2011-07-14 |
20110171320 | Methods to extend vision to infrared wavelengths - In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can normally be seen by the naked eye. Light reflected from the object is then perceived with an enhanced eye. The enhanced eye contains an up-conversion material optically coupled to the photoreceptors. Up-conversion materials absorb in the infrared and luminesce in the visible. Particles containing such materials are delivered to the eye where they are optically coupled to the retina or photoreceptor cells and nearby tissues. There they provide in-situ up-conversion of infrared frequencies (from about 700 to about 11,000 nm) to the otherwise unaided eye. | 2011-07-14 |
20110171321 | ELASTOMERIC ARTICLE HAVING A BROAD SPECTRUM ANTIMICROBIAL AGENT AND METHOD OF MAKING - A method for impregnating a polymer with a bioactive material includes preparing a bioactive metal solution having a bioactive metal, a first solvent in which the bioactive metal is insoluble and a second solvent in which the bioactive metal is slightly soluble. The method also includes soaking the polymer in the bioactive metal solution. Another method for impregnating a polymer with a bioactive material includes soaking the polymer in a swelling solvent followed by soaking the polymer in a bioactive metal solution having the bioactive metal and a solvent in which the bioactive metal is slightly soluble. A bioactive metal-impregnated polymer is prepared by soaking a polymer in a saturated bioactive metal solution comprising a bioactive metal, a swelling solvent in which the bioactive metal is insoluble, and a second solvent in which the bioactive metal is slightly soluble. | 2011-07-14 |
20110171322 | FLOCCULATING ALGICIDE COMPOSITION - Flocculating algicide composition constituted by the following elements in the proportions described: aluminium sulphate 21%, copper sulphate 28.5%, sodium bisulphate 9.3%, ethylenediaminetetraacetic acid 12.5%, diatomaceous earth 28.7%. | 2011-07-14 |
20110171323 | METHODS AND KITS TO PREDICT PROGNOSTIC AND THERAPEUTIC OUTCOME IN SMALL CELL LUNG CANCER - Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the identification, and kits that facilitate the identification. The methods and kits involve detecting the expression of specific microRNA. | 2011-07-14 |
20110171324 | METHOD OF TREATING OR PREVENTING DISEASE IN BEES - The invention is directed to a method of a method of treating or preventing disease in honeybees, a method of promoting the health of honey bees and to a method of increasing the production of honeybees in a hive or colony. | 2011-07-14 |
20110171325 | Systems and Methods for Treating Pain Using Brain Stimulation - The invention comprises systems and methods for treating nociceptive pain including at least one force-regulatable device in mechanical, electrical, or chemical communication with at least one brain area identified as processing nociceptive pain signals. The force-regulatable device acts to alter the nociceptive pain signals in a brain area to alleviate nociceptive pain. | 2011-07-14 |
20110171326 | Pharmaceutical material for psoriasis treatment - One embodiment of a pharmaceutical material for psoriasis treatment includes a liquid preparation by extracting herbs selected from the group consisting of | 2011-07-14 |
20110171327 | GUAVA PULP COMPOSITION - The present invention discloses a guava pulp (also referred to as pulp composition) of a particle size not greater than 0.25 mm which does not contain seeds and peels from the guava and has a lycopene concentration which is 1 to 2 folds higher than the lycopene concentration in the guavas from which the pulp is obtained. The invention further discloses uses of the pulp composition as starting material for obtaining guava oleoresin and lycopene, and as antioxidant. | 2011-07-14 |
20110171328 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES - The invention discloses a pharmaceutical composition for synergistically treating and preventing diabetic complication. The composition contains 1-deoxynojirimycin and fagomine, and the weight ration of the 1-deoxynojirimycin to the fagomine is 0.5-5:1. | 2011-07-14 |
20110171329 | METHOD FOR TREATMENT OF NEURAL INJURIES - A method for treating neural damage with a composition prepared from roots of | 2011-07-14 |
20110171330 | ANTI-FEVER BOTANICAL COMPOSITION AND USES THEREOF - According to at least one aspect of the present invention, a botanical anti-fever composition is provided. In at least one embodiment, the botanical composition comprises a therapeutically effective amount of admixture of parts or extracts of at least one plant species from each of genus | 2011-07-14 |
20110171331 | METHOD FOR INCORPORATING EMOLLIENT OILS INTO BAR SOAP PRODUCTS - A method for incorporating high levels of emollient oils into soap, soap/synthetic combinations, or all synthetic soap products is provided. A highly stable dispersion of an emollient oil is prepared and subsequently blended into the soap composition. | 2011-07-14 |
20110171332 | LEUCOJUM BULB EXTRACTS AND USE THEREOF - The present invention relates to | 2011-07-14 |
20110171333 | Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products - The present invention relates to | 2011-07-14 |
20110171334 | ANTIBACTERIAL SUBSTANCE DM0507 AND UTILIZATION OF THE SAME - An object is to provide a more potent novel antimicrobial active substance, which is derived from a naturally occurring substance and has a broad antimicrobial spectrum, and an antimicrobial active substance DM0507 obtained by a production process comprising the following steps (a) to (d):
| 2011-07-14 |